A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With Metastatic RCC

New York

Charleston

Myrtle Beach

Atlanta

Albany

Columbus

Indianapolis

Madison

Minneapolis

Chicago

Shreveport

San Antonio

Los Angeles

Portland

Worcester

Antwerp

Brussels

Bordeaux

Caen

Lyon

Paris

Berlin

Hamburg

Hanover

Heidelberg

Munich

Aviano

Pavia

Rome

Barcelona

Madrid

Pamplona

Valencia

Glasgow

Swansea

Cambridge

London

Manchester